Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis

Cellceutix Corporation (OTCQB: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that the Company has just received the final toxicology report for Brilacidin-OM.  Cellceutix is developing Brilacidin-OM as a new treatment for oral mucositis, a common and often debilitating inflammation and ulceration that occurs in the mouth as a side effect of certain cancer treatments, including chemotherapy and radiation therapy.

Cellceutix is reviewing the report, which will be added to finalize the already prepared Investigational New Drug (IND) application for submission to the U.S. Food and Drug Administration seeking approval to commence a Phase 2 clinical trial of Brilacidin-OM as soon as possible.

“The past week was full of great news for us; that enrollment for the Phase 2b trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections will be completed this month, the statistical data on our anti-psoriasis drug Prurisol showed that it attained it’s primary endpoint in a Phase 1 trial, and now the data to complete the IND for Brilacidin-OM.  We look forward to the IND submission in a bid to fill an area of great unmet medical need to the nearly half a million patients that suffer the painful effects of oral mucositis every year,” commented Leo Ehrlich, Chief Executive Officer of Cellceutix.

Mr. Ehrlich added, “On a broader perspective, the question has been posed to me about what last week’s FDA approval of The Medicines Company’s oritavancin, a one-time treatment for ABSSSI, means to Brilacidin.  First, we congratulate The Medicines Company on their approval.  Candidly, we do not view oritavancin as a potential competitor to our Brilacidin because of several key differentiators, namely pharmacokinetic profiles and subsequent implications.  Oritavancin is a lipoglycopeptide, the same class of drug as Durata Pharmaceutical’s Dalvance® (Dalbavancin), and both drugs have a very long half-life of approximately one to two weeks.  This means that the drug remains in a patient’s system for a considerable period following dosing, which has the potential for contraindication with other medicines and questions concerning metabolism and drug resistance.  Brilacidin, a new class of drug, has a half-life of only 13 to 16 hours, a time frame that we believe is ideal for a one-time treatment, while greatly decreasing the chance of resistance developing.  Further, Brilacidin in its clinical trials is being tested compared to daptomycin, a superior drug to vancomycin, which was the comparator arm in the pivotal trials of oritavancin and Dalvance.  Overall, in addition to the direct comparison with ABSSSI, we look at our asset as offering much more potential as an antibiotic, especially with room temperature formulations paving the way for possibly treating a wide range of other indications, such as diabetic foot ulcer infections, ophthalmic infections and otitis media.  ABSSSI alone is more than a billion-dollar market and growing, and there is room for everyone with the best drug taking the lion’s share of dollar sales.  So while we applaud a new therapeutic option for patients, we are not concerned about the approval of oritavancin.”